Risk Factors Update Summary

• The company's listing on The Nasdaq Capital Market may be at risk due to non-compliance.
• The company acquired assets from Klydon and Pet Labs Pharmaceuticals for $2 million and $6 million, respectively.
• Failure to maintain compliance with listing standards could lead to delisting and negatively impact shareholders.
• The company expects to be heavily dependent on future isotopes sales, with an accumulated deficit of $23 million as of December 31, 2023.
• The company may face risks related to dependence on third parties for the production and commercialization of isotopes.
• The company is still early in research and development efforts for isotopes like Mo-100 and U-235.
• The company may face challenges in obtaining necessary approvals for research and development efforts, potentially leading to the loss of significant rights.
• Significant costs incurred as a public company may impact financial performance and shareholder value.
• The company has not yet built a functioning manufacturing plant for isotopes and has not demonstrated commercial production capabilities.
• The company's future prospects are directly tied to the end market demand for enriched isotopes and the successful commercialization of their technology.